GSK major holder reports 4.93% voting stake

GSK plc files a Form 6-K reporting a TR-1 notification that a major holder has 4.930000% of its voting rights, representing 200,296,898 voting rights in total.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

GSK plc files a Form 6-K reporting a TR-1 notification that a major holder has 4.930000% of its voting rights, representing 200,296,898 voting rights in total. These are held through ordinary shares and ADRs, with no additional voting rights linked to financial instruments.

The filing shows 88,958,040 voting rights (2.190000%) attached to ordinary shares and 111,338,858 voting rights (2.740000%) through ADRs, together making up the reported 4.930000% position.

Key Figures

Voting rights percentage: 4.930000% Total voting rights held: 200,296,898 voting rights Ordinary share voting rights: 88,958,040 voting rights +1 more

4 metrics

Voting rights percentage 4.930000% Resulting situation when threshold was crossed

Total voting rights held 200,296,898 voting rights Resulting situation when threshold was crossed

Ordinary share voting rights 88,958,040 voting rights Ordinary shares GB00BN7SWP63, 2.190000% of voting rights

ADR voting rights 111,338,858 voting rights ADRs US37733W2044, 2.740000% of voting rights

Key Terms

TR-1, major holdings, voting rights attached to shares, financial instruments, +1 more

5 terms

TR-1 regulatory

"TR-1: Standard form for notification of major holdings"

A TR-1 is a financial form used by investors to report significant ownership stakes in a company, typically when they acquire or dispose of a large number of shares. It helps keep the market informed about major shareholders and potential changes in control, allowing other investors to make better-informed decisions. This transparency encourages fair trading and reduces surprises related to ownership shifts.

major holdings regulatory

"TR-1: Standard form for notification of major holdings"

Major holdings are the largest assets—such as specific stocks, bonds, cash positions, or other investments—that make up a significant share of a fund’s or investor’s portfolio. They matter because these big positions largely determine performance and risk; like the star players on a team, they can swing returns and reveal whether an investment is heavily concentrated in a particular company, industry, or strategy.

voting rights attached to shares financial

"% of voting rights attached to shares (total of 8.A)"

financial instruments financial

"% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)"

Financial instruments are assets or contracts that hold monetary value and can be bought, sold, or traded. They serve as tools for investors to grow, protect, or transfer money, much like how a ticket or voucher can be used to access goods or services. These instruments help individuals and organizations manage financial goals and risks across different markets and economic conditions.

ADRs financial

"ADRs US37733W2044 | | 111338858 | | 2.740000"

American Depositary Receipts (ADRs) are certificates issued by a U.S. bank that stand in for shares of a foreign company, allowing those shares to be bought and sold on U.S. stock exchanges in U.S. dollars. Think of an ADR as a local ticket representing a foreign stock: it makes trading, settlement, and tax reporting simpler for U.S. investors, but still exposes them to risks like currency moves, different accounting rules, and foreign corporate practices.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does GSK (GSK) disclose in this May 2026 Form 6-K?

The Form 6-K discloses a TR-1 notification of a major holding in GSK. A holder reports 4.930000% of GSK’s voting rights, equal to 200,296,898 voting rights, split between ordinary shares and ADRs.

How large is the major holding reported in GSK (GSK) voting rights?

The major holding represents 4.930000% of GSK’s voting rights. This corresponds to 200,296,898 total voting rights in the company, combining exposure through ordinary shares and American Depositary Receipts (ADRs).

How are the reported GSK (GSK) voting rights split between ordinary shares and ADRs?

The position includes 88,958,040 voting rights (2.190000%) via ordinary shares and 111,338,858 voting rights (2.740000%) via ADRs. Together, these holdings account for the total 4.930000% voting interest reported in the notification.

Are any financial instruments disclosed in the GSK (GSK) TR-1 major holdings notice?

The TR-1 notice shows no voting rights held through financial instruments. Both sections for financial instruments, 8B1 and 8B2, report zero voting rights, indicating the 4.930000% position is entirely via shares and ADRs.

What total number of GSK (GSK) voting rights does the major holder control?

The major holder controls 200,296,898 voting rights in GSK. This figure is the sum of voting rights from ordinary shares and ADRs and corresponds to 4.930000% of the company’s total voting rights.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/01/2026 - 11:08 AM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BN7SWP63

Issuer Name

GSK PLC

UK or Non-UK Issuer

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Dodge & Cox

City of registered office (if applicable)

San Francisco

Country of registered office (if applicable)

USA

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

5. Date on which the threshold was crossed or reached

28-Apr-2026

6. Date on which Issuer notified

30-Apr-2026

7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	4.930000	0.000000	4.930000	200296898
Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
Ordinary GB00BN7SWP63		88958040		2.190000
ADRs US37733W2044		111338858		2.740000
Sub Total 8.A	200296898		4.930000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.
Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

12. Date of Completion

30-Apr-2026

13. Place Of Completion

San Francisco, California, United States of America

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: May 01, 2026

	By:/s/ VICTORIA WHYTE --------------------------

	Victoria Whyte
	Authorised Signatory for and on
	behalf of GSK plc

Source: View Original Filing on SEC EDGAR